Metastasized murine oral squamous cell carcinoma cells induce intratumoral polymorphonuclear myeloid derived suppressor cells

Sumi,Shigeki; Umemura,Naoki; Takayama,Eiji; Ohkoshi,Emika; Adachi,Makoto; Mizuno-Kamiya,Masako; Inagaki,Toshihiro; Kawaki,Harumi; Sumitomo,Shinichiro; Kondoh,Nobuo

doi:10.3892/or.2017.5575

Metastasized murine oral squamous cell carcinoma cells induce intratumoral polymorphonuclear myeloid derived suppressor cells

Authors:
- Shigeki Sumi
- Naoki Umemura
- Eiji Takayama
- Emika Ohkoshi
- Makoto Adachi
- Masako Mizuno-Kamiya
- Toshihiro Inagaki
- Harumi Kawaki
- Shinichiro Sumitomo
- Nobuo Kondoh
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Asahi University School of Dentistry, Gifu 501‑0296, Japan, Department of Oral Biochemistry, Asahi University School of Dentistry, Gifu 501‑0296, Japan, Department of Natural and Medicinal Chemistry, Faculty of Pharmaceutical Sciences Aomori University, Aomori 030-0943, Japan, Chemistry Laboratory Department of Management and Information Studies, Asahi University School of Business Administration, Gifu 501-0296, Japan, Department of Oral and Maxillofacial Surgery, Division of Reparative and Regenerative Medicine, Institute of Medical Science, Mie University Graduate School of Medicine, Tsu 514-8507, Japan
Published online on: April 11, 2017 https://doi.org/10.3892/or.2017.5575
Pages: 2897-2904

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myeloid derived suppressor cells (MDSCs) localize to hematopoietic organs and peripheral blood during inflammation or tumor tissues and lymph nodes in the presence of a tumor. However, whether there are differences in MDSCs found in the primary tumor and metastases is unknown. In the present study, we established a cell line of metastasized tumor cells to a lymph node, L5-11, which were derived from the Sq-1979 mouse buccal mucosa squamous cell carcinoma cell line. We then analyzed tumor immunogenicity, especially with regard to MDSCs, to clarify the differences between the primary tumor and metastases, using an isogenic heterotopic tumor transplantation model. Our data showed that the population of intratumoral MDSCs, especially polymorphonuclear MDSCs in the lymph node metastasis model were significantly increased compared with syngeneic grafts from the primary cell line Sq-1979 after 21 days. Furthermore, we identified that the lymph node metastasis cell line had increased expression of genes that promote the expansion of MDSCs, tumor growth and metastasis. Hence, these data suggest that tumor immunosuppression can occur via activation of MDSCs. However, further examination is required to clarify whether all or a subset of these factors from the lymph node metastasis tumor cells are required to induce intratumoral MDSCs.

View Figures

View References

1	Kalnins IK, Leonard AG, Sako K, Razack MS and Shedd DP: Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity. Am J Surg. 134:450–454. 1977. View Article : Google Scholar : PubMed/NCBI
2	Grandi C, Alloisio M, Moglia D, Podrecca S, Sala L, Salvatori P and Molinari R: Prognostic significance of lymphatic spread in head and neck carcinomas: Therapeutic implications. Head Neck Surg. 8:67–73. 1985. View Article : Google Scholar : PubMed/NCBI
3	Yu CC, Chen PN, Peng CY, Yu CH and Chou MY: Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis. Oncotarget. 7:20180–20192. 2016.PubMed/NCBI
4	Ohnishi K, Yamaguchi M, Erdenebaatar C, Saito F, Tashiro H, Katabuchi H, Takeya M and Komohara Y: Prognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinoma. Cancer Sci. 107:846–852. 2016. View Article : Google Scholar : PubMed/NCBI
5	Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, et al: Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 118:2603–2614. 2012. View Article : Google Scholar : PubMed/NCBI
6	Condamine T, Ramachandran I, Youn JI and Gabrilovich DI: Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 66:97–110. 2015. View Article : Google Scholar : PubMed/NCBI
7	Heim CE, Vidlak D, Scherr TD, Kozel JA, Holzapfel M, Muirhead DE and Kielian T: Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection. J Immunol. 192:3778–3792. 2014. View Article : Google Scholar : PubMed/NCBI
8	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
9	Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, et al: Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 14:211–220. 2013. View Article : Google Scholar : PubMed/NCBI
10	Nagaraj S, Schrum AG, Cho HI, Celis E and Gabrilovich DI: Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 184:3106–3116. 2010. View Article : Google Scholar : PubMed/NCBI
11	Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ and Wiltrout RH: Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/alphaCD40 therapy. J Immunol. 192:5821–5829. 2014. View Article : Google Scholar : PubMed/NCBI
12	Marvel D and Gabrilovich DI: Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest. 125:3356–3364. 2015. View Article : Google Scholar : PubMed/NCBI
13	Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, et al: HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 207:2439–2453. 2010. View Article : Google Scholar : PubMed/NCBI
14	Khaled YS, Ammori BJ and Elkord E: Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res. 2014:8798972014. View Article : Google Scholar : PubMed/NCBI
15	Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 18:1254–1261. 2012. View Article : Google Scholar : PubMed/NCBI
16	Youn JI, Collazo M, Shalova IN, Biswas SK and Gabrilovich DI: Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 91:167–181. 2012. View Article : Google Scholar : PubMed/NCBI
17	Wynn TA: Myeloid-cell differentiation redefined in cancer. Nat Immunol. 14:197–199. 2013. View Article : Google Scholar : PubMed/NCBI
18	Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, et al: Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 41:947–959. 2014. View Article : Google Scholar : PubMed/NCBI
19	Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al: Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 7:121502016. View Article : Google Scholar : PubMed/NCBI
20	Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, Luyckx A, De Baetselier P and Van Ginderachter JA: Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8⁺ T-cell activation events. Eur J Immunol. 43:2930–2942. 2013. View Article : Google Scholar : PubMed/NCBI
21	Luo M, Hou L, Li J, Shao S, Huang S, Meng D, Liu L, Feng L, Xia P, Qin T, et al: VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin. Cancer Lett. 373:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
22	Goel HL and Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
23	De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A and Maggiolini M: HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res. 15:R642013. View Article : Google Scholar : PubMed/NCBI
24	Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014. View Article : Google Scholar : PubMed/NCBI
25	Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, Epling-Burnette P, Van Bijnen S, Dolstra H, Cannon J, et al: Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 123:4595–4611. 2013. View Article : Google Scholar : PubMed/NCBI
26	Miao HQ, Lee P, Lin H, Soker S and Klagsbrun M: Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J. 14:2532–2539. 2000. View Article : Google Scholar : PubMed/NCBI
27	Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA, Tamagnone L and Mazzone M: Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 24:695–709. 2013. View Article : Google Scholar : PubMed/NCBI
28	Hu ZQ, Zhou SL, Zhou ZJ, Luo CB, Chen EB, Zhan H, Wang PC, Dai Z, Zhou J, Fan J, et al: Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection. Oncotarget. 7:51733–51746. 2016.PubMed/NCBI